Two New York State departments filed an amendment on Wednesday that would allow medical marijuana businesses to provide hemp-derived compounds such as CBD to patients.
The measure, which was introduced by the Departments of Health and Agriculture and Markets, is designed to “enhance” the state’s medical cannabis program while also lowering manufacturing costs for licensed facilities. Patients would also reap the cost-savings benefits under the regulatory amendment.
“The Department remains committed to growing New York State’s Medical Marijuana Program responsibly, as evidenced by the work we have done to enhance the program since its launch nearly four years ago,” Health Department Commissioner Howard Zucker said in a press release. “This is yet another example that will help improve the program for patients and registered organizations.”